Sequencing whole genomes for personalized medical treatment may become possible with new-generation sequencing applications, such as targeted resequencing, whole-genome de novo sequencing, transcriptome sequencing, and microRNA profiling (1) (2) (3) (4) (5) . Targeted resequencing of an extremely large gene or multiple disease-related genes has the unique advantage of allowing the identification of genetic alterations that can be targeted by gene therapy, such as the use of rapamycin for the mTOR pathway for the NF1 (neurofibromin 1) gene and the use of antisense oligonucleotides for read-through of premature stop codons and exon skipping to treat Duchenne muscular dystrophy (6 -9 ) . Research studies that have used these new-generation sequencing applications, although few in number, have emphasized the importance of analyzing human genome sequences and have suggested that sequence information will have a noteworthy impact on molecular medicine (10 ) .
Targeted resequencing by next-generation sequencing (NGS) 6 techniques requires the targeted enrichment of DNA samples. Currently, PCR-based methods are the most widely used for preparing a genomic sample for sequencing purposes (11) (12) (13) (14) ; however, PCR methods fall short of meeting the technological needs for sequencing highly complex genomic regions and in large-scale genomic studies. PCR methods cannot amplify very long sequences reliably, and multiplex enrichment of thousands of sequences is difficult (14 ) . Several technologies have been developed for targeted enrichment by sequence capture, including solid phase-based microarrays and solution phase-based methods (15) (16) (17) (18) . Owing to the limited availability of the SureSelect™ system (Agilent Technologies) and the complexity of synthesizing padlock probes, we used the microarray method in this study (16 ) . This recently developed technology selects targeted sequences by hybridization to an oligonucleotide microarray and demonstrates great potential for the efficient enrichment of specific, large high-complexity genomic regions of interest (14, 15, 19, 20 ) . Combining this technology with NGS produces a powerful sequencing tool that has the potential to be implemented in a clinical diagnostics laboratory. Aside from such issues as test reporting and ethical considerations, 2 main technical hurdles need to be overcome besides targeted DNA enrichment: management of massive amounts of data and potential interference from highly homologous sequences (e.g., pseudogenes) (10 ) . Because the NGS technology is so new, QC of the sequence data (including the accuracy of reads, quality scores for reads, and sequencingcoverage needs) has not yet been well defined, but it will need to be before NGS technology can be used routinely in molecular diagnostics laboratories (10, 21 ) . Therefore, the goal of this study was to benchmark this new sequence capture and enrichment (SCE) NGS technology by comparing it with the current gold standard, Sanger sequencing, in the application of targeted resequencing.
We selected the NF1 gene as the clinical target in this pilot study. Neurofibromatosis type 1, a common tumor-predisposing disorder that occurs in 1 of 3000 births, is caused by autosomal dominant mutations in a single gene, NF1 (17q11.2). Neurofibromatosis type 1 presents with a wide range of manifestations that can lead to serious disabilities, including cognitive problems (22) (23) (24) (25) . In view of the complexity of the premature stop codon mutations in NF1, the existence of 7 pseudogenes and pseudogene sequences on different chromosomes, and the fact that this gene consists of 58 exons and harbors complex genomic structures, such as repetitive sequences and Alu sequences, NF1 is an ideal clinical target for evaluating the effectiveness of the SCE-NGS method for clinical applications (24, 26 -29 ) . In the present study, we successfully enriched targeted sequences with a specifically designed NF1 capture microarray and developed detailed methods for data analysis, including removal of interferences due to highly homologous pseudogenes.
Materials and Methods

DNA SAMPLES
Two neurofibromatosis type 1-positive samples (with known NF1 genotypes) were obtained from Coriell Cell Repositories and coded as CN1 (NA11601) and CN2 (NA11602). DNA quantity and quality were measured with a NanoDrop spectrophotometer (Thermo Scientific). The DNA concentration was 373 ng/L for CN1 and 344 ng/L for CN2. To ensure sample quality for sequence capture of the targeted region, we prepared 80 L of each sample and shipped it to NimbleGen (Roche NimbleGen) for targeted sequence capture.
DESIGN OF THE OLIGONUCLEOTIDE MICROARRAY FOR NF1
REGION CAPTURE
The NF1 region to be captured is at genomic position 26 446 121 to 26 728 821 (UCSC hg18, NCBI Build 36). Long oligonucleotide probes (Ͼ60mers) were chosen from the target region, and 15mer frequency and the uniqueness of probes in the genome were evaluated to exclude repetitive regions from probe selection [see (30 ) for details]. We selected 385 000 probes specifically to tile the target region (NF1) with high density. We used a uniqueness score of 1 during the design to avoid capturing pseudogene sequences.
TARGETED SEQUENCE CAPTURE BY THE CUSTOMIZED
OLIGONUCLEOTIDE MICROARRAY
The methods used for sequence capture and elution followed previously described protocols (31 ) . In brief, DNA was nebulized to yield fragments from 250 bp to approximately 1 kb in size, and a 22mer linker was added to both ends. The DNA fragments were then hybridized to the NF1 sequence-capture array for 3 days. After hybridization and stringent washing, the DNA fragments remaining on the array (mostly from target regions) were eluted off the array and amplified with 22mer linkers to generate enough DNA template for downstream applications. After amplification, the product was tested for enrichment level by quantitative PCR with 4 QC control loci to determine the degree of capture success. These 4 QC loci, which are conserved in both human and mouse genomes, have been empirically determined to accurately predict enrichment with several different experimental designs. Finally, the amount of captured DNA (after elution) for GS FLX sequencing was measured by spectrophotometry, on the assumption that an A 260 value of 1.0 is equivalent to approximately 50 g/mL double-stranded DNA.
GS FLX SEQUENCING AND COMPARATIVE DATA ANALYSIS
The captured DNA was sequenced with the GS FLX instrument at the 454 Sequencing Service Center (Branford, CT). Because of the relatively small size of the sequence-capture fragments (250 bp to approximately 1 kb), the nebulization step was not performed. The Low Molecular Weight DNA Protocol (32 ) was used to prepare the 454 GS FLX sequence-ready librar-ies. The DNA-sequencing libraries for the 2 samples (CN1 and CN2) were prepared separately before amplification by emulsion PCR (emPCR). The emPCR followed the steps described in the GS FLX emPCR Method Manual (33 ). The 2 prepared samples (after emPCR amplification) were loaded in a single 2-lane gasket PicoTiterPlate device (70 ϫ 75 mm; Roche/454) and sequenced in a GS FLX system with standard Roche/454 protocols. The 454 pyrosequencing data were collected after a 7-h run on the GS FLX system.
The Roche/454 gsMapper was used initially to analyze all raw sequence reads generated from the GS FLX system. We used NextGENe™ software (version 1.12; SoftGenetics) to analyze the GS FLX data (.sff files) to investigate the possibility of analyzing NGS data with Windows-based software packages (see Supplemental Data Analysis in the Data Supplement that accompanies the online version of this article at http://www. clinchem.org/content/vol56/issue1). We fully sequenced both samples via Sanger sequencing (with specific primer sets used to avoid amplification of pseudogenes) to confirm any sequence variants detected with the SCE-NGS method.
Results
NF1 SCE
In the present study, we used NimbleGen's long oligonucleotide microarray with 385 000 features to design specific probes to capture entire NF1 sequences located in 17q11.2 (a 282 700-bp region). Capture efficiencies (-fold enrichment), which were estimated by quantitative PCR before and after capture with 4 QC control loci, were 336-fold and 586-fold increases for samples CN1 and CN2, respectively. Both enrichments passed the QC standard (Ͼ100-fold enrichment), although CN1 was less enriched (an approximately 42% reduction) than CN2.
GS FLX SEQUENCING AND REFERENCE-MAPPING ANALYSIS
After SCE with the customized NF1 capture array, both SCE samples (CN1 and CN2) were sequenced by the GS FLX genome sequencer. The data were analyzed with the gsMapper software. Sample CN1 had a mean read length of 210 bp and 254 743 high-quality (HQ) reads, 52.0% of which were uniquely mapped to the reference genome (UCSC hg18, NCBI Build 36). Of the uniquely mapped HQ reads, 59.3% were on the targeted NF1 loci (Table 1) . Sample CN2 had a mean read length of 222 bp and 271 921 HQ reads, 70.0% of which were uniquely mapped to the reference genome. Of the uniquely mapped HQ reads, 58.8% were on the targeted NF1 loci ( Table 1 ). The reference-mapping analyses showed similar percentages of HQ reads (59.3% for CN1, 58.8% for CN2) mapped to the targeted NF1 region, suggesting that the SCE-NGS method had a reasonable within-run reproducibility and capture specificity (approximately 60%), although the 2 samples differed with respect to the degree of enrichment (336-fold vs 586-fold) and the percentage of HQ reads uniquely mapped to the reference genome (52.0% vs 70.0%). In addition, the percentage of reads mapped to chromosomes other than the targeted 17q11.2 was not large (Ͻ4%, Table 1 ) for both samples analyzed, suggesting that the design of the sequence-capture array was unique and specific for the corresponding target; however, this supposition was not confirmed with base pair-level analyses of the entire data set. 
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SEQUENCE ANALYSIS, SANGER SEQUENCING CONFIRMATION, AND PSEUDOGENE ALIGNMENT
To further analyze all captured sequences in both intron and exon regions, we used the Windows-based NextGENe software package to confirm the results obtained from the Linux-based 454 gsMapper software and to generate lists of all sequence variants found by the SCE-NGS method. To ensure result accuracy, we used a high stringency of alignment identity (Ն95%) to align HQ reads to the reference genome. In general, the gsMapper and NextGENe software produced similar results. Sample CN1 had 58.4% of the HQ reads uniquely mapped to the reference genome, and 59.4% of them were mapped on the targeted NF1 loci. Sample CN2 had 68.5% of the HQ reads uniquely mapped to the reference genome, and 64.0% of them were mapped on the targeted NF1 loci. The unmapped reads to the genome (with a mean of 110 bp) are much shorter than the mean of all HQ reads, indicating these short reads are possible artifacts. All variants detected in exons and at intron/exon boundaries were confirmed by bidirectional Sanger sequencing with a capillary sequencer (ABI 3130 Genetic Analyzer; Applied Biosystems). According to the genotyped result (34 ), sample CN1 has a heterozygous de novo Alu sequence (approximately 483 bp) inserted 44 bp upstream of exon 42 and immediately adjacent to a poly(A/T) stretch, which causes deletion of the downstream exons during splicing. Although the probe design for the NF1 sequence-capture microarray ignores the repetitive sequences, it does not rule out possible de novo insertions. Therefore, it is reasonable to expect partial detection of the inserted Alu sequences, either from the 3Ј sequences before the insertion or the 5Ј sequences after the insertion, owing to the tiling design of the NF1 capture microarray. Both the capture probe design and the sequencing coverage map showed sequence reads in this particular region (Fig. 1) , suggesting that our expectation was valid; however, we initially did not identify the heterozygous de novo Alu insertion after performing the targeted reference-mapping analysis. A possible explanation for this scenario is that the large size of the insertion might prevent alignment with the reference sequence. Therefore, in addition to reference-mapping analysis, we assembled contigs de novo for the HQ unmatched reads (remaining from the targeted reference-mapping analysis) and aligned them with the genome with low stringency (50% identity). We then partially observed the inserted Alu sequence, as we had expected (see Fig. 1 in the online Data Supplement). In addition, the number of the inserted-sequence reads (coverage) is low, which further challenges the detection of the inserted Alu sequence. We found 16 reads of the inserted alleles and 32 reads of wild-type alleles that crossed the insertion boundary. Although the inserted Alu sequence could be detected when extra care was taken, the low stringency used in the analysis generated too many nonunique mappings (structure variations) and thus led to too many false-positive calls.
In addition to the inserted Alu sequence, we also conducted a detailed investigation of all sequence variants found in sample CN1 by the SCE-NGS method ( Table 2 ). To consider clinically important variants, we first focused on and reported changes in all exons and within Ϯ25 bp of each exon. After filtering out all known nonpathogenic single-nucleotide polymorphisms with the dbSNP database (http://www.ncbi. nlm.nih.gov/projects/SNP/) and eliminating clinically unrelated homopolymers, we identified 17 sequence variants in sample CN1. Bidirectional Sanger sequencing of the entire NF1 coding region confirmed 3 sequence variants, leaving 14 variants that were discrepant with the Sanger sequencing data ( Table 2 ). Because of the inherent variation of the SCE and the pyrosequencing-based NGS platform used in this study, our second data-analysis strategy was to apply 2 parameters to determine true sequence variants. The first parameter was sequence coverage depth, and the second was the percentage of the heterozygous-allele calls. In accordance with Smith et al. (35 ) and our current data set, we decided to set the parameters to a sequence coverage depth of Ͼ30ϫ and the percentage of heterozygous-allele calls to within 40%-60% to obtain reliable sequence data. Our data set showed that approximately 208.3 kb of 282 kb of the NF1 gene had 30ϫ sequence coverage. The reason that some positions either were not covered or had low coverage may be related to low capture efficiency, the exclusion of repetitive regions from the probe design, or potential variations caused by sample-processing steps, such as fragmentation and addition of linkers.
Use of these settings allowed us to filter out discrepant sequence variants detected by the SCE-NGS method that were potentially due to pyrosequencing errors. This step eliminated 10 discrepant results and left 4 undeterminable variants (Table 2) . Interestingly, these 4 discrepant sequence variants were all located in the largest exon, exon 21 (441 bp). Analysis of the similarity of the exon 21 sequence of the functional NF1 gene (on chromosome 17) to its pseudogenes (on chromosomes 2, 12, 14, 15, 18, 21, and 22) explained the remaining 4 sequencing discrepancies between the SCE-NGS and the Sanger sequencing results. Alignment analysis showed a high homology (Ͼ97%) between NF1 exon 21 and its pseudogenes on chromosomes 12 and 15 (Table 2, Fig. 2 ; see Fig. 2 in the online Data Supplement). These alignment results resolved all discrepant sequence variants found in exon 21, whereas the 2 primary parameters (sequencing coverage and base change percentage) failed to filter out SCE-NGS data for potential false-positive sequence changes, even with Ͼ100ϫ sequencing coverage ( Table 2) .
Sample CN2 had a single-base deletion in the coding region (exon 28) that caused a frameshift mutation (36 ) . In our SCE-NGS study, we detected the same single-base deletion, but it was in exon 37. This difference in exon location was due to differences between the current nomenclature and the nomenclature used in early 1990s. In addition to this deletion, we also detected 9 more sequence variants with the SCE-NGS method (Table 3) . Bidirectional Sanger sequencing confirmed only 3 sequence variants. Of the remaining 6 discrepant sequence variants, 2 were in exon 13, and 4 were in exon 21 (Table 3 ). Because sequencing coverage of all 6 of these variants was Ͼ30ϫ and because the rule of heterozygous-allele call failed to explain discrepancies between the SCE-NGS data and the Sanger sequencing data, we assumed pseudogene interference. An alignment analysis showed that sequence variants detected in exon 13 by SCE-NGS matched with pseudogenes located on chromosomes 2 and 22 (Table 3 , Fig. 3) . Similarly, sequence variants detected in exon 21 by SCE-NGS matched with pseudogenes located on chromosomes 12 and 15 (Table 3 In the present study, all pseudogene sequences were manually checked and were successfully identified and removed from both of the tested samples (Tables 2 and 3). When this information was combined with that from the analysis that used defined parameters, all discrepancies between the SCE-NGS results and the Sanger sequencing results were resolved (100% concordance), leaving 3 true sequence variants for CN1 (in addition to the undetected Alu insertion) and 3 true sequence variants for CN2 (in addition to the singlebase deletion).
Discussion
The primary concern and challenge in applying the SCE-NGS method as a diagnostic tool are having the capability to detect large de novo insertions, especially direct-repeat sequences (i.e., Alu) in a heterozygous format. Although insertions are not commonly present in all genetic diseases, insertions are present in rela- tively high percentages in patients with neurofibromatosis type 1 (37 ) . In our study, we were able to detect the heterozygous inserted Alu sequence by first performing reference-mapping with all HQ reads, followed by de novo assembly with low alignment stringency (50%) with the remaining unmatched reads. In other words, the inserted Alu sequence could have been missed if only the reference-mapping analysis had been used. This circumstance could have led to a potential false-negative clinical interpretation. Use of de novo assembly with low alignment stringency helped to detect the inserted Alu sequence, but it also generated too many false-positive calls. A second concern with the SCE-NGS method is the lack of definitive parameters for QC of the sequence data. For clinical applications, the major hurdle in the use of the SCE-NGS method is how to set a reliable cutoff threshold for determining true sequence variants when multiple variants from the reference sequence are detected. Although the requirement for sequencing coverage to obtain reliable results has previously been investigated (35 ) , we found no recommendations regarding a threshold for confidently establishing a heterozygous-allele call when heterozygous sequence variants are detected. Such a threshold value needs to be established to rule out potential pyrosequencing errors, and we have established a range of 40%-60% for heterozygous-allele calls based on our data set. For the discrepant cases with heterozygousallele calls less than but close to 40%, 2 possible factors might cause this scenario. First, pyrosequencing may exhibit different systematic errors compared with other NGS technologies. Second, sequence artifacts, such as short reads, homopolymers, and the presence of pseudogenes, can interfere with the percentage of heterozygous-allele calls. A large sample set needs to be studied before specific QC guidelines can be recommended for the use of this new technology in routine diagnostics laboratories. At this time, routine Sanger sequencing is still required to confirm data generated by NGS.
When multiple pseudogenes (or highly homologous sequences) exist, the algorithm used for data analysis is particularly important in studies that use a sample-enrichment process with capture-based technologies and highly sensitive NGS for gene sequence analysis. In our study, the initial whole-chromosome mapping analysis of both CN1 and CN2 showed statistically nonsignificant sequences captured from NF1 pseudogenes; however, we found that all of the discrepancies between SCE-NGS and Sanger sequencing data were due to pseudogene interference. Such interfer- ence suggests that NGS substantially amplified the signals from trace nonspecific sequences captured by SCE and thereby decreased the clinical specificity of the SCE-NGS method compared with Sanger sequencing. Before spending efforts to redesign capture probes and to reoptimize target-probe hybridization conditions, we explored the use of a software approach to eliminate interference by pseudogenes (or highly homologous sequences). We applied a data-analysis algorithm, dual-mode reference-mapping (DMRM), to the CN1 and CN2 data sets to filter out all detected sequence variants originating from pseudogenes. Basically, the first mode of this analysis algorithm is to align all 454 HQ reads (from both samples) to the reference genome, one chromosome at a time. Reads that match perfectly (Ն50 bp with 95% identity) to multiple locations are allowed to match to all possible locations in the entire genome. This mode generates 25 separated reference-sequence files (with much reduced data sizes) containing sequences specific to each chromosome (including X and Y) and chromosome 17 for NF1 sequences only. The second mode is then to realign all 454 HQ reads simultaneously with all newly generated reference-sequence files (with reduced sizes). Taking advantage of the relatively long sequence read length produced by the GS FLX system, we identified the genomic signature of each highly homologous sequence captured (from different chromosomes) and removed the sequences. Once these sequences are removed, the true sequence variants (if any) detected by the SCE-NGS method can be determined. Our initial data analysis of CN1 and CN2 showed that the DMRM algorithm successfully identified and removed all pseudogene sequences. This procedure resolved all remaining discrepancies between the SCE-NGS data and the Sanger sequencing confirmation data. In addition to reducing the risk of reporting false positives due to interference by highly homologous sequences, the reference files (with reduced sizes) generated from the first mode can be reused to analyze other NF1 SCE-NGS data in much less time, which is another advantage of the DMRM. Further testing of the DMRM analysis is currently underway with more SCE-NGS data to reveal its utility.
In conclusion, by avoiding massive PCR preparation and sequencing of multiple large regions of interest simultaneously, the SCE-NGS method has potential for use in clinical settings. Compared with other short- 
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read NGS platforms (i.e., the Applied Biosystems SOLiD and Illumina GAII systems), the long sequence reads provided by the GS FLX system not only allows better assembly for detecting large insertions (especially repetitive sequences) but also allows easier identification of genomic signatures from highly homologous sequences. This study evaluated the utility of microarrays for targeted sequence capture and addressed the issues regarding data management and interference by highly homologous sequences (e.g., pseudogenes) through development of a step-by-step data-analysis strategy and the prototype of DMRM analysis. In addition, we recommend further studies to compare the microarray capture method with solution phase-based enrichment methods, such as Agilent's SureSelect.
